Vivos Therapeutics, Inc.
VVOS
$2.57
$0.000.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.93% | 19.41% | -11.36% | -17.77% | -22.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.93% | 19.41% | -11.36% | -17.77% | -22.26% |
| Cost of Revenue | -1.80% | 8.17% | -2.50% | -25.99% | -11.20% |
| Gross Profit | 33.60% | 26.36% | -17.12% | -12.37% | -30.01% |
| SG&A Expenses | -7.71% | -31.31% | -22.20% | -26.06% | -32.23% |
| Depreciation & Amortization | -2.67% | -2.03% | -16.57% | -11.83% | -14.29% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.28% | -24.29% | -18.71% | -26.29% | -28.09% |
| Operating Income | 27.34% | 57.14% | 24.38% | 31.83% | 32.68% |
| Income Before Tax | -24.99% | 65.09% | -120.96% | 30.05% | 61.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.99% | 65.09% | -120.96% | 30.05% | 61.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.99% | 65.09% | -120.96% | 30.05% | 61.48% |
| EBIT | 27.34% | 57.14% | 24.38% | 31.83% | 32.68% |
| EBITDA | 28.42% | 59.01% | 24.66% | 32.41% | 33.26% |
| EPS Basic | 77.38% | 87.05% | 5.16% | 44.13% | 72.67% |
| Normalized Basic EPS | 77.38% | 87.05% | 5.17% | 44.33% | 72.67% |
| EPS Diluted | 77.14% | 87.05% | 5.16% | 44.13% | 72.64% |
| Normalized Diluted EPS | 77.38% | 87.05% | 5.17% | 44.33% | 72.67% |
| Average Basic Shares Outstanding | 452.52% | 169.64% | 132.99% | 25.19% | 40.96% |
| Average Diluted Shares Outstanding | 452.52% | 169.64% | 132.99% | 25.19% | 40.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
